{"filing":{"accession_number":"0001193125-26-380184","cik":"0001853921","ticker":null,"company_name":"Scribe Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-02","report_date":"2026-09-02","primary_document":"sctx-20260902.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1853921/000119312526380184/sctx-20260902.htm"},"events":[{"id":31299,"run_id":28713,"accession_number":"0001193125-26-380184","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses quarterly financial results including collaboration revenue ($1.9M), R\u0026D expenses ($8.8M), G\u0026A expenses ($2.5M), and net loss ($6.5M), along with balance sheet items and cash position. The filing is material as it provides investors with the company's financial performance and runway guidance (funding into H1 2029).","company_name":"Scribe Therapeutics, Inc.","ticker":null,"filing_date":"2026-09-02","form":"8-K","submitted_at":null,"items":[{"id":34132,"accession_number":"0001193125-26-380184","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses quarterly financial results including collaboration revenue ($1.9M), R\u0026D expenses ($8.8M), G\u0026A expenses ($2.5M), and net loss ($6.5M), along with balance sheet items and cash position. The filing is material as it provides investors with the company's financial performance and runway guidance (funding into H1 2029).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:10:34.700672+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34132,"accession_number":"0001193125-26-380184","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses quarterly financial results including collaboration revenue ($1.9M), R\u0026D expenses ($8.8M), G\u0026A expenses ($2.5M), and net loss ($6.5M), along with balance sheet items and cash position. The filing is material as it provides investors with the company's financial performance and runway guidance (funding into H1 2029).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:10:34.700672+00:00","company_name":"Scribe Therapeutics, Inc.","ticker":null,"filing_date":"2026-09-02"}]}